Pre-made Eblasakimab benchmark antibody ( Whole mAb, anti-IL13RA1 therapeutic antibody, Anti-CD213A1/CT19/IL-13Ra/NR4 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Eblasakimab biosimilar, Whole mAb, Anti-IL13RA1 Antibody: Anti-CD213A1/CT19/IL-13Ra/NR4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Eblasakimab biosimilar, Whole mAb, Anti-IL13RA1 Antibody: Anti-CD213A1/CT19/IL-13Ra/NR4 therapeutic antibody |
|---|---|
| INN Name | Eblasakimab |
| Target | IL13RA1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 4hwe:HL/4hwb:HL |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | ASLAN Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Atopic dermatitis |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL13RA1 |
| Package |
